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Abstract
Purpose: Evidence is lacking whether the number of breast tumor-initiating cells (BT-ICs) directly correlates with the
sensitivity of breast tumors to chemotherapy. Here, we evaluated the association between proportion of BT-ICs and
chemoresistance of the tumors.
Methods: Immunohistochemical staining(IHC) was used to examine the expression of aldehyde dehydrogenase 1 (ALDH1)
and proliferating cell nuclear antigen, and TUNEL was used to detect the apoptosis index. The significance of various
variables in patient survival was analyzed using a Cox proportional hazards model. The percentage of BT-ICs in breast cancer
cell lines and primary breast tumors was determined by ALDH1 enzymatic assay, CD44
+/CD24
2 phenotype and
mammosphere formation assay.
Results: ALDH1 expression determined by IHC in primary breast cancers was associated with poor clinical response to
neoadjuvant chemotherapy and reduced survival in breast cancer patients. Breast tumors that contained higher proportion
of BT-ICs with CD44
+/CD24
2 phenotype, ALDH1 enzymatic activity and sphere forming capacity were more resistant to
neoadjuvant chemotherapy. Chemoresistant cell lines AdrR/MCF-7 and SK-3rd, had increased number of cells with sphere
forming capacity, CD44
+/CD24
2 phenotype and side-population. Regardless the proportion of T-ICs, FACS-sorted CD44
+/
CD24
2 cells that derived from primary tumors or breast cancer lines were about 10–60 fold more resistant to chemotherapy
relative to the non- CD44
+/CD24
2 cells and their parental cells. Furthermore, our data demonstrated that MDR1 (multidrug
resistance 1) and ABCG2 (ATP-binding cassette sub-family G member 2) were upregulated in CD44
+/CD24
2 cells. Treatment
with lapatinib or salinomycin reduced the proportion of BT-ICs by nearly 50 fold, and thus enhanced the sensitivity of breast
cancer cells to chemotherapy by around 30 fold.
Conclusions: These data suggest that the proportion of BT-ICs is associated with chemotherapeutic resistance of breast
cancer. It highlights the importance of targeting T-ICs, rather than eliminating the bulk of rapidly dividing and terminally
differentiated cells, in novel anti-cancer strategies.
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Introduction
Chemotherapy is an important component in the treatment
paradigm for breast cancers. However, despite a rapid shrinkage
in tumor mass following chemotherapeutic cycles, breast cancers
may recur and develop distal metastasis later on. We now know
that molecular mechanisms responsible for chemotherapeutic
resistance of breast cancers are rather complicated, which involve
overexpression of ATP-binding cassette transporters, anti-apo-
ptotic factors [1] [2] and kinases for DNA repairing [3,4].
Targeting any single molecule is not sufficient to reverse
chemotherapeutic resistance [5], suggesting that multiple molec-
ular pathways may contribute to the sensitivity of breast cancer
cells to chemotherapy. Therefore, it is more important to identify
and eliminate the subpopulation of cancer cells that are refractory
to chemotherapeutic drugs.
Recently, accumulating evidence demonstrates that a wide
variety of malignant tumors may be driven by a small subset of
‘‘tumor-initiating cells (T-ICs)’’ [6,7] that display similar biological
features of normal stem cells. Breast tumor-initiating cells (BT-ICs)
form spherical clusters (‘‘mammosphere’’) in suspension cultures
due to their self-renewal capacity [8]. BT-ICs also overexpress
aldehyde dehydrogenase 1 (ALDH1) and bear the phenotype of
CD44
+/CD24
2 [7,9]. It has been shown that BT-ICs are more
resistant to chemotherapy than non-BT-ICs due to multiple
molecular mechanisms [10], including overexpression of ATP-
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surviving [12,13] and DNA damage repairing [12,13]. Further-
more, self-renewing T-ICs can be selectively enriched or induced
by chemotherapy [11]. However, whether the percentage of T-ICs
within human tumors predict chemoresistance remains unknown
[14].Therefore, we hypothesize that the proportion of BT-ICs may
correlate with chemotherapeutic sensitivity of breast cancers, and
reducing BT-ICs may reverse chemoresistance in the malignancy.
In our present study, we found that ALDH1 expression was
associated with chemotherapeutic efficacy and clinical outcome of
breast cancer patients, Furthermore, breast cancers containing a
higher proportion of BT-ICs were more resistant to chemother-
apy. BT-ICs isolated from various primary tumors or cell lines are
equally resistant to chemotherapeutic drugs. In addition, reducing
the number of breast T-ICs with Lapatinib and salinomycin
sensitized BT-ICs to chemotherapy. These data suggest that the
proportion of BT-ICs contributes to chemotherapeutic resistance
of breast cancer.
Results
ALDH1 expression correlates with clinical outcome of
breast cancer patients
ALDH1 serves as a specific marker for normal and malignant
human mammary stem cells [9]. To determine whether the
number of BT-ICs is associated with chemotherapeutic efficacy,
we performed immunohistochemical staining to examine ALDH1
expression in 192 cases of invasive ductal carcinomas of the breast
obtained by core-needle biopsy prior to pre-operative neoadjuvant
chemotherapy, and evaluated the expression level following the
criteria of a previous study [15]. Here, 38 out of the 192 cases
(19.8%) of breast cancers were classified as high ALDH1
expression (.20% positive cancer cells) (Table 1). The treatment
paradigms including endocrine therapy and chemotherapy were
comparable in patients with high or low ALDH1 expression
(Table S1). ALDH1 expression was significantly associated with
clinical staging, differentiation, tumor size and lymph node
metastasis of the patients(Figure 1A, Table 1 ). More importantly,
according to the Response Evaluation Criteria in Solid Tumors
(RECIST), the clinical response rate, including partial and
complete remission (PR+CR) was higher in patients with low
ALDH1 than those with high ALDH1 (81% vs. 53%, x
2=15.926;
p,0.001) (Figure S1). In addition, breast cancers with low
ALDH1 expression in their biopsies obtained prior to chemother-
apy had higher percentage of apoptotic cells and lower percentage
of proliferating cells in the corresponding surgical specimens
obtained after neoadjuvant chemotherapy (Figure 1B, p,0.001),
suggesting that ALDH1 expression in breast cancers is reversely
correlated with apoptosis and proliferation inhibition induced by
chemotherapy. Moreover, patients with low ALDH1 had longer
overall survival (OS) and disease free survival (DFS) as compared
with those with high ALDH1. The cumulative overall survival rate
at 50 months for patients with low ALDH1 was 82.3%, but was
only 55.1% for those with high ALDH1 (Log Rank=7.987,
p=0.005, Figure 1C, Table S2). Similarly, the cumulative disease
free survival rate at 50 months for patients with low ALDH1 was
77.3%, significantly higher than that for those with high ALDH1
expression (42%, Log Rank=19.347, p,0.001, Figure 1D,Table
S2). We next performed a Cox multivariate analysis of DFS, taking
account of tumor size, clinical staging, differentiation, lymph node
metastasis, estrogen receptor(ER), human epidermal growth factor
receptor 2(Her2), proliferating cell nuclear antigen(PCNA) status,
apoptosis index (AI) and ALDH1 expression as categorical
variables. In the final multivariate COX regression model,
ALDH1 expression in breast cancer patients was associated with
poor survival prognosis (hazard ratio=2.197, p=0.013) indepen-
Table 1. Correlation among clinicopathologic status and the expression of ALDH1, PCNA and apoptosis.
characteristics Subgroup ALDH1 PCNA AI
#20% .20% P #20% .20% P No. Mean±SD P
Age #40 years 51 11 0.916 36 26 0.227 62 1.4760.61 0.721
.40 years 103 27 86 44 130 1.4460.58
ER Positive 113 26 0.541 92 47 0.242 53 1.4160.60 0.578
Negative 41 12 30 23 139 1.4660.59
PR Positive 96 22 0.668 77 41 0.359 118 1.4860.57 0.540
Negative 58 16 45 29 74 1.4360.60
HER2 Positive 21 7 0.304 14 14 0.102 28 1.4560.59 0.727
Negative 133 31 108 56 164 1.4160.59
Clinical Stage II 114 6 ,0.001 96 24 ,0.001 120 1.5060.52 0.116
III 40 32 26 46 72 1.3760.67
Grade I 15 1 ,0.001 13 3 0.145 16 1.3960.52 0.834
II 86 32 64 45 109 1.4460.59
III 14 53 45 22 67 1.4860.61
Tumor size T1 31 0 ,0.001 31 0 ,0.001 31 1.6560.40 ,0.001
T2 102 15 82 35 117 1.5160.55
T3 21 23 9 35 44 1.1460.70
Node Metastasis 1–3 131 23 ,0.001 106 48 0.013 154 1.5260.51 0.030
$4 22 14 16 22 38 1.3560.67
ALDH1=aldehyde dehydrogenase 1; AI=apoptotic index, percentage of apoptotic cancer cells.
doi:10.1371/journal.pone.0015630.t001
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used as an independent prognostic factor for breast cancers (Table
S3). Collectively, our data suggest that expression of ALDH1, a
marker of BT-IC, may indicate chemotherapy resistance and poor
clinical outcome in breast cancer patients.
BT-IC proportion correlates with poor clinical response to
neo-adjuvant chemotherapy
In order to directly evaluate the contribution of BT-IC to
chemotherapeutic response, we isolated primary cancer cells from
the biopsies of 26 breast cancer patients obtained prior to
chemotherapy and correlated ALDH1 enzymatic activity,
CD44
+/CD24
2 phenotype and mammosphere forming rate with
the efficacy of chemotherapy. Among all the 26 patients who
received neoadjuvant chemotherapy of FEC (5-Fluorouracil
500mg/m
2, Epirubucin 90mg/m
2 and Cyclophosphamide
500mg/m
2) regimen for 4 cycles, 13 patients had partial or
complete response (PR/CR), while the other 13 patients had stable
or progressive diseases (PD/SD) (Table S4). The percentage of
ALDH1
+ cells was significantly higher in breast cancers with PD/
SD than those with PR/CR (11.54%65.65% vs. 2.08%61.42%,
p=0.007, Figure 2A). Similarly, breast cancers with PD/SD had
higher percentage of CD44
+/CD24
2cancer cells than those with
PR/CR (35.0%69.13% vs. 1.5660.33%, p,0.001, Figure 2B).
Moreover, mammosphere formation of primary cancer cells in
breast tumors with PD/SD was 10–20 fold higher than those with
PR/CR (p,0.001, Figure 2C). These findings demonstrate that a
higher proportion of T-ICs is associated with poor clinical
response of primary breast cancers to chemotherapy, suggesting
that the number of BT-ICs plays a pivotal role in chemothera-
peutic resistance of breast cancers.
BT-ICs from various primary tumors and cell lines are
resistant to chemotherapy
To evaluate whether T-ICs isolated from the primary breast
tumors of different individuals or from different breast cancer
lines are resistant to chemotherapy, we sorted for putative T-ICs
from both clinical specimens and cell lines and compared the
chemotherapeutic sensitivity of T-ICs with non-T-ICs. First, we
examined the proportion of BT-ICs in AdrR/MCF-7 and SK-
3rd, the breast cancer lines induced to be resistant to adriamycin
and epirubicin. As shown in Figure 3A, the percentage of AdrR/
MCF-7 cells and SK-3rd cells with the phenotype of CD44
+/
CD24
2 was significantly higher than the parental MCF-7 cell
line and SKBR3 cell line (42.3864.80% vs. 1.82%60.64%,
64.3462.62% vs. 0.68%60.16%, p,0.001). In agreement, the
percentage of mammospheres formed in AdrR/MCF-7 line and
SK-3rd line was significantly higher than the parental MCF-7
line and SKBR3 line (5.1260.22% vs. 1.3860.49%,
13.661.02% vs. 0.2260.13% , p,0.001, Figure S2A and
S2B). Next we investigated whether the chemotherapeutic
sensitivity of T-ICs differ among individual tumors. Cell
Counting Kit-8 was used to determine the number of viable
cells upon treatment with adriamycin at increasing concentra-
tions. As shown in Figure 3B, FACS-sorted CD44
+/CD24
2 cells
have a prominent survival advantage over non-CD44
+/CD24
2
cells and their parental cells. Upon adriamycin treatment, the
survival of CD44
+/CD24
2 MCF-7 and AdrR/MCF-7 were
similar and were about 10–60 fold higher than those of non-
CD44
+/CD24
2 cells and their parental cells. Likewise, CD44
+/
CD24
2 SK-3rd were about 25-fold more resistant to epirubicin
than the non-CD44
+/CD24
2 SK-3rd and the parental SKBR3
cells. CD44
+/CD24
2 primary cells were about 25-fold more
resistant to epirubicin than the non-CD44
+/CD24
2 cells. In the
absence of chemotherapy, survival was comparable in the cells
with or without CD44
+/CD24
2 phenotype. Furthermore,
regardless the proportion of T-ICs in the primary tumors or
the breast cancer lines, adriamycin or epriubicin significantly
increased the apoptosis of non-CD44
+/CD24
2cells but not that
of CD44
+/CD24
2 cells determined by Annexin V staining
(Figure 3C). Moreover, our data demonstrated that MDR1 and
ABCG2 expression were both upregulated in CD44
+/CD24
2
cells from various cell lines and primary tumors (Figure 3D,
Table S5), along with increased side-population (SP) (Figure S3).
These results indicate that BT-ICs are the subpopulation of
cancer cells in both the primary tumors and various cell lines
that are resistant to chemotherapy and thus may determine the
chemotherapeutic sensitivity of breast cancer.
Reducing the proportion of BT-ICs sensitizes breast
cancer cells to chemotherapy
Based on the above observations, we further investigated
whether reducing the proportion of BT-ICs may sensitize breast
cancers to conventional chemotherapy. Recent studies reported
that lapatinib [16], a double EGFR/HER2 inhibitor, selectively
killed the BT-ICs upon chemotherapy. In addition, salinomycin,
an antimicrobial and anticoccidial agent, efficiently inhibits self-
renewal of BT-ICs in breast cancer cell lines and reduces the
expression of BT-IC specific genes in breast cancer tissues [17].
Here, CD44
+/CD24
2 BT-ICs sorted from MCF-7 line constitu-
tively express EGFR, much higher than that in the parental MCF-
7 and the AdrR/MCF-7 cells (Figure S4). More importantly,
treatment with salinomycin or lapatinib significantly reduced
mammosphere formation(p,0.001, Figure 4A and Figure S5) and
the percentage of ALDH1
+ cells by approximately 10–100 fold in
CD44
+/CD24
2 BT-ICs isolated from MCF-7 cells, primary cells
and SK-3rd cells (p,0.001, Figure 4B, Figure S6A and S6B).
Although chemotherapy alone did not influence the cloning
efficiency of CD44
+CD24
2 MCF-7 and SK-3rd cells, addition of
lapatinib or salinomycin significantly reduced it by approximately
10–30 fold (p,0.001; Figure 4C, Figure S7). Moreover, combined
treatment with adriamycin and lapatinib or salinomycin synergis-
tically increased cell death from 27.8%60.85% and 32.8%62.6%
to 75.1%64.1%% and 77.9%64.8% (Figure 4D), suggesting that
reducing the proportion of BT-ICs enhances chemotherapeutic
sensitivity in breast cancers.
Figure 1. Aldehyde dehydrogenase (ALDH1) expression correlates with clinical outcome of breast cancer patients. (A)
Immunohistochemical staining shows tumors with poor clinical response (progressive or stable disease, PD/SD) to neo-adjuvant chemotherapy
express high ALDH1 (.20% positive cancer cells) in pre-chemotherapy samples, and tumors with partal response (PR) express low ALDH1 (#20%
positive cancer cells). High proliferating cell nuclear antigen (PCNA)(.25% positive cancer cells) and poor apoptosis are observed in tumors with PD/
SD after neo-adjuvant chemotherapy. Representative images of ALDH1 (6200), PCNA (6200) and Terminal deoxynucleotidyl transferase (TdT)-
mediated dUTP labeling (TUNEL,6400). (B) Surgically removed tumor samples obtained after neoadjuvant chemotherapy from patients with low
ALDH1 have higher percentage of TUNEL-staining cells (r=20.892, p,0.001), but lower percentage of PCNA-staining cells (r=0.804, p,0.001). (C–
D)Kaplan-Meier curves with log rank tests show statistical difference in overall survival (Log Rank=7.987, p=0.005) (C) and disease-free survival (Log
Rank=19.347, P,0.001) (D) between patients with high ALDH1 expression and low ALDH1 expression.
doi:10.1371/journal.pone.0015630.g001
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The example of ALDH1
+ primary cancer cells in the progressive disease (PD) samples (symbol ‘‘N’’, n=13) is 13.2% whereas 0.4% in partial response
(PR) samples (symbol ‘‘X’’, n=13) (p=0.007). All these 26 cancer tissue samples were obtained before chemotherapy. (B) Breast tumors with
progressive or stable disease(PD/SD) (7 cases) have more cancer cells CD44
+/CD24
2 phenotype than those with PR (7 cases) (35.0%69.13% vs.
1.56%60.33%, p,0.001). (C) Mammosphere formation of primary cancer cells in breast tumors with PD/SD is 10–20 fold higher than those with PR
(15.2% vs. 0.83%, p,0.001).
doi:10.1371/journal.pone.0015630.g002
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resistant MCF-7 (AdrR/MCF-7) cells and epirubicin resistant SKBR3 (sk-3rd) cells with the phenotype of CD44
+CD24
2 is significantly higher than
parental MCF-7 line and SKBR3 line tested by FACS (42.3864.80% vs. 1.82%60.64%, 64.3462.62% vs. 0.68%60.16%, p,0.001). (B) FACS-sorted
Tumor-Initiating Cells Indicate Chemoresistance
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It has been noted that tumor-initiating cells, or cancer stem
cells, in solid malignancies are resistant to chemotherapy, but
evidence is lacking whether the number of breast tumor-initiating
cells directly correlates with chemotherapeutic sensitivity of the
tumor. Here, we demonstrated that the percentage of ALDH1-
positive cancer cells was associated with clinical chemotherapeutic
response and prognosis in breast cancer patients. Breast tumors
containing a higher proportion of BT-ICs were more resistant to
chemotherapy. BT-ICs themselves were resistant to chemotherapy
and their proportion in breast tumors determined chemothera-
peutic sensitivity of the tumors. Furthermore, reducing the number
of BT-ICs sensitized breast cancer cells to chemotherapy.
Growing evidence showed that the proportion of T-ICs varies
among different primary tumors and different cancer cell lines
[11,12]. Breast cancer cells may develop biological features
analogous to stem cells, especially when they undergo epithelial-
mesenchymal transition (EMT) [18] or acquire amplification of
human epidermal growth factor receptor 2 (HER2) gene [19].
Therefore, T-ICs are present in various proportions in primary
breast tumors. Here, we employed specific markers to quantify the
proportion of BT-ICs in primary breast cancers or breast cancer
cell lines. Based on our data of flow cytometry, the CD44
+/
CD24
2 and ALDH1
+ primary breast cancer cells varied from
1.8% to 48% and 0.4% to 23.6% respectively, which was verified
by ALDH1 immunohistochemical staining. This suggests that the
proportion of T-ICs is different in individual breast tumors.
Chemotherapy has been shown to selectively enrich BT-ICs in
the bulk of breast cancer cells. In contrast to non-BT-ICs that are
probably not responsible for cancer recurrence or metastasis
following chemotherapy [20,21], growing evidences suggest that
T-ICs are a subpopulation of cancer cells that drive tumor growth
and recurrence. In our study, we analyzed the expression level of
ALDH1 in primary breast cancers prior to pre-operative
neoadjuvant chemotherapy and the breast cancer cells without
drug exposure. These results indicated that poor clinical response
and prognosis were associated with high proportion of BT-ICs that
are resistant to chemotherapy. Similarly, compared with parental
cells and non-CD44
+/CD24
2 cells, CD44
+/CD24
2 cells were
10–60 fold more resistant to chemotherapy. Taken together, these
data suggest that the proportion of BT-ICs plays a key role in
chemotherapeutic resistance and post-treatment recurrence of
breast cancers, and thus contributes to the poor prognosis of breast
cancer patients.
Chemotherapy is less efficient in BT-ICs due to a variety of
mechanisms. In light of our results, compared with parental cells
and drug resistant cells, CD44
+/CD24
2 cells are more likely to
survive toxic insults probably due to up-regulated MDR1 and
ABCG2. Like the normal tissue stem cells, multidrug resistance
(MDR) transporters protect dormant cancer stem cells, and MDR
is constitutively expressed at stable and high levels in T-ICs with
stem-cell like features. Thus, BT-ICs are believed to be resistant to
chemotherapy prior to receiving the treatment, which leads to
their enrichment following chemotherapy. Several signaling
pathways such as the epidermal growth factor receptor (EGFR),
Hedgehog, Notch and Wnt signaling pathways [22] are involved
in the regulation of treatment resistance in BT-ICs. Nevertheless,
all these mechanisms have complicated cross link with one another
[23]. Therefore, it is not sufficient to kill BT-ICs, especially in
clinical therapy only by interfering with a single molecule.
The number of T-ICs is controlled by their own self-renewal,
which is regulated by several signaling pathways such as the
Hedgehog, Notch and Wnt pathways [22]. Inhibition of key
regulatory pathways responsible for self-renewal could reduce the
number of T-ICs. Recently, some studies showed that cancer stem
cells can be targeted by lapatinib [16] and salinomycin [17]. We
found that mammosphere formation rate and the percentage of
cells with enzymatic activity of ALDH1 or CD44
+/CD24
2 profile
in MCF-7 and SK-3rd cells decreased significantly in the presence
of the lapatinib or salinomycin. Moreover, combined treatment
with chemotherapy and lapatinib/salinomycin synergistically,
rather than additively, increases breast cancer cell death, implying
that targeting T-ICs may eradicate chemotherapeutic resistance
and post-treatment recurrence in breast cancers. Furthermore,
Lapatinib has been shown to sensitize cancer cells to chemother-
apeutic drugs by inhibiting the EGFR, P-glycoprotein (Pgp) and
breast cancer resistance protein (BCRP) [24].
The mechanisms of the drug resistance in T-ICs are very
complicated. Our data suggest that the proportion of T-ICs
directly correlates with chemotherapeutic resistance of breast
cancer. Thus, it is important to quantify the proportion of BT-ICs
to predict chemotherapeutic sensitivity. It also implies that anti-
cancer therapy should shift from attempts to eliminate the bulk of
rapidly dividing and terminally differentiated cells to targeting T-
ICs within a tumor.
Materials and Methods
Ethics statement
At the time of initial diagnosis, all patients had provided consent
in the sense that their tumor samples could be used for
investigational purposes. Institutional approval from local research
ethical committee was obtained for the conduct of the study
(Internal Review and the Ethics Boards of the Sun Yat-Sen
Memorial Hospital, Sun Yat-Sen University). Data were analyzed
anonymously. Patients provided written consent so that their
samples and clinical data could be used for investigational
purposes.
Patients and tumor specimens
Tumor tissues of primary invasive ductal carcinomas of the
breast were obtained from 192 female patients with stage IIB and
III prior to pre-operative neoadjuvant chemotherapy in the breast
tumor center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen
University from Feb 2003 to Dec 2008. All the patients underwent
pre-operative neoadjuvant chemotherapy with 2 to 6 cycles of
FEC regimen (5-Fluorouracil 500mg/m
2, Epirubucin 90mg/m
2
and Cyclophosphamide 500mg/m
2). Subsequently, the patients
underwent total mastectomy or breast conservation. The patients
with breast conservation received postoperative radiotherapy
delivered to the entire breast using photon beams (median dose
CD44
+CD24
2 MCF-7 and CD44
+CD24
2 AdrR/MCF-7 was about 10–60 fold higher resistant to adriamycin relative to the parental cells and non-
CD44
+CD24
2 cells. CD44
+CD24
2 SK-3rd and primary cells were about 25 fold higher resistant to epirubicin relative to parental cells and non-
CD44
+CD24
2 cells by using cell viability assay. (C)Compared with non-BT-ICs, chemotherapy (adriamycin or epriubicin 0.5mg/ml for 24 hours)
increased Annexin V positive cells of non-CD44
+/CD24
2cells, which derived from tumors with high or low proportion T-ICs, MCF-7, AdrR/MCF-7 and
SK-3rd breast cancer cell lines containing different number of T-ICs (p,0.001). (D) MDR1 (multidrug resistance 1) and ABCG2(ATP-binding cassette
sub-family G member 2) protein expression is both up-regulated in CD44
+/CD24
2 cells from different cell lines and primary cells. All the experiments
were repeated 3 times independently.
doi:10.1371/journal.pone.0015630.g003
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15630Figure 4. Reducing the proportion of BT-ICs sensitizes breast cancer cells to chemotherapy. (A)Treatment with salinomycin or lapatinib
significantly reduced mammosphere formation in CD44
+/CD24
2 MCF-7 cells and primary cells by approximately 10 fold relative to DMSO control
(p,0.001). (B) Treatment with salinomycin or lapatinib reduced the percentage of ALDH1
+ in CD44
+/CD24
2 MCF-7 cells by 5–10 fold and primary
cells by 50 fold. (C) Addition of lapatinib or salinomycin reduced the percentage of cloning efficiency of CD44
+CD24
2 MCF7 cells by approximately
10–30 fold (p,0.001). (D) The sensitivity of CD44
+/CD24
2 MCF-7 cells to adriamycin increased in the presence of lapatinib or salinomycin, as the dead
cells increased from 27.8%60.85% and 32.8%62.6% to 75.1%64.1%% and 77.9%64.8% respectively determined by FACS analysis of Annexin V and
PI staining(*p,0.01, **p,0.001, mean6SD). All the experiments were repeated 3 times independently.
doi:10.1371/journal.pone.0015630.g004
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beams, for a total median dose of 66Gy. According to the clinical
response of neoadjuvant chemotherapy determined by the
Response Evaluation Criteria in Solid Tumors (RECIST),
adjuvant FEC or Taxotere was selectively administered in the
patients with PR/cCR or PD/SD. Endocrine therapy was
administered for patients with positive hormonal receptor. Distal
metastasis was not found in these patients upon diagnosis, but was
identified in 54 cases during post-operative follow-up, overall
survival (OS) and disease free survival (DFS) were analyzed as the
clinical endpoints, the median follow-up time is 50 months.
Fresh tumor tissues were obtained from another 26 female
breast cancer patients before any treatment via ultrasound-guided
vacuum-assisted Vacora biopsy system (Bard Biopsy System,
Tempe, AZ). The samples were received in the laboratory within
20 min and immediately mechanically disaggregated and digested
with collagenase as described [7]. Single-cell suspensions were
obtained by filtration through a 40mm filter.
Immunohistochemistry
The level of ALDH1 and PCNA was tested by immunohisto-
chemistry staining in paraffin-embedded tissue sections. Rabbit
monoclonal ALDH1A1 antibody (ab52492, Abcam) (1:100
dilutions) and anti-PCNA antibody (ab29, Abcam) (1:6000
dilutions) were used as primary antibody. The rabbit IgG or
mouse IgG was added as the negative control in each case. The
proportion of positive tumor cells was evaluated by two
pathologists who were blinded to the study endpoints and used
to quantify the degree of the immunostaining. For the statistical
analysis, we divided cases into two groups: low expression
(ALDH1
+#20% or PCNA#25%) and high expression
(ALDH1
+.20% or PCNA.25%) [9].
Terminal deoxynucleotidyl transferase (TdT)–mediated
dUTP labeling (TUNEL)
TUNEL assay was done using an In situ Apoptosis Detection
Kit (R&D Systems). Briefly, after digesting with Protease K, TdT
reaction mix was applied to the cells for incubation at 37uCf o r
60 min, followed by incubation with streptavidin horseradish
peroxidase for 10 min. The final reaction of the product was
visualized by 3,39-diaminobenzidine. Approximately 1,000 tumor
cells were counted (4006) in each section, and apoptotic
index(AI) was expressed as the percentage of TUNEL-positive
tumor cells.
Cell culture and treatment
Cells (1000cells/ml) were cultured in suspension in serum-free
DMEM-F12 (Gibco), supplemented with B27 (1:50, Invitrogen),
20 ng/mL EGF (BD Biosciences), 0.4% bovine serum albumin
(Sigma), and 4 mg/ml insulin (Sigma) to form mammospheres
[25]. In all the mammosphere experiments, primary plating data
are provided. Wild type (WT) MCF-7 human breast cancer cells
were obtained from American Type Culture Collection (ATCC)
and grown according to standard protocols. Adriamycin resistant
MCF-7 (AdrR /MCF-7) cells were selected in stepwise increasing
concentrations beginning at 10
28 M Adriamycin. When cells were
able to survive at any given concentration of the drug, they were
passaged in the concentrations which were 1.5-fold higher. Cells
were subsequently obtained which were able to survive in 10
25 M
adriamycin. Parental SKBR3 and epirubicin resistant SKBR3
(SK-3rd) cells were cultured in RPMI1640 containing 10%FBS
[11]. Drug lapatinib (GW572016) and Salinomycin (Sigma, s4526)
was dissolved in DMSO.
Flow cytometry
Flow cytometric cell testing and sorting was performed on
single-cell suspensions derived from cell lines and primary tumor
specimens using an Epics Altra flow cytometer (Beckman Coulter).
CD44 and CD24 expression was analyzed in cells following
incubation in trypsin-EDTA or dissociation with a pipette and
passage through a 40-mm sieve. At least 1610
5 cells were pelleted
by centrifugation at 500 g for 5 min at 4uC, resuspended in 2mLo f
FITC-conjugated anti-CD44 (PharMingen) and 5mL of PE-
conjugated anti-CD24 (PharMingen), then incubated at 4uCi n
the dark for 30 min. The labeled cells were washed twice and
analyzed. The ALDEFLUOR kit (StemCell Technologies, Dur-
ham, NC, USA) was used to test ALDH enzymatic activity. As the
negative control, for each sample of cells an aliquot was treated
with 50 mmol/L diethylaminobenzaldehyde (DEAB), a specific
ALDH inhibitor. SP analysis was performed as described [26]. In
all the experiments, verapamil 50mmol/L was added with dye to
confirm the SP. Dead cells were quantified using the Annexin V
Apoptosis detection kit (Calbiochem, PF032).
Western blotting
Protein extracts were resolved through SDS-PAGE, transferred
to polyvinylidene difluoride membranes (Amersham Pharmacia
Biotech), probed with ABCG2 antibody (1:500,San Cruz, SC-
18841) and Mdr-1 antibody (1:200, San Cruz,SC-71557), then
with HRP-conjugated anti-rabbit or anti-mouse IgG secondary
antibody, and visualized by chemiluminescence.
RT-PCR assays
MDR1 and EGFR mRNA expression were monitored by semi-
quantitative RT-PCR. The sequence of the primers used for RT-
PCR was as follow: MDR1 forward: 59-AACGGAAGCCAGAA-
CATTCC-39; MDR1 reverse: 59-AGGCTTCCTGTGGCAAA-
GAG-39 [27]; EGFR forward: 59-AGCCATGCCCGCATTAG
CTC-39; EGFR reverse: 59-AAAGGAATGCAACTTCCCAA-39
[28]. DNA products were run on 1.5% agarose gel and visualized
by ethidium bromide using UV light. Data presented are
representative of at least three independent experiments.
Cell viability assay
Cells were seeded in a 96 well plate with 100uL media at a
density of 1610
4 per well and incubate (37uC, 5% CO2) overnight
to allow the adherent cells to attach to the wells. Adherent cells
were cultured in media with 10% FBS, and mammospheric cells
cultured in suspension media without FBS. Then the cultured cells
were incubated (37uC, 5% CO2) with adriamycin for 24 hours.
20uL cell counting kit-8 solution (CCK-8,Alexis Biochemical
Corp., San Diego, CA) was added to each well and incubated
(37uC, 5% CO2) for 4 hours. Optical density was read at 560nm
and subtracted background at 670nm.
Statistical analysis
All statistical analyses were carried out using SPSS 13.0 (SPSS,
Chicago, IL). Student’s t-test and One-Way ANOVA were used to
analyze the relationship between apoptotic index and clinicopath-
ologic characteristics, and the difference between ALDH1,
CD44
+/CD24
2 expression or mammosphere formation rate in
the cell lines and clinical response. Chi-Square Test was applied to
analyze the relationship between ALDH1,PCNA expression and
clinicopathologic features. To measure the association between
pairs of variables, Spearman order correlation were run. Survival
curves were plotted by the Kaplan-Meier method and compared
by the log-rank test. The significance of various variables for
Tumor-Initiating Cells Indicate Chemoresistance
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the multivariate analysis. All experiments for cell cultures were
performed at least in triplicate. Results were expressed as mean 6
SD. P,0.05 in all cases was considered statistically significant.
Supporting Information
Figure S1 The clinical response of neoadjuvant chemo-
therapy with ALDH1 expression. According to Response
Evaluation Criteria in Solid Tumors (RECIST), partial response
(PR) ,clinical complete response (cCR), progressive or stable
disease (PD/SD) were 16, 3, and 19 respectively among the
patients with high ALDH1expression. In contrast, the patients
with ALDH1 low expression were 123, 12 and 19 respectively.
There was significant difference between the ALDH1 expression
and clinical response (81% vs. 53%, x
2=15.926; p,0.001).
(TIF)
Figure S2 Mammospheres forming in chemotherapy
sensitive and resistant breast cancer cells. (A) Represen-
tative images of mammospheres for parental MCF-7, AdrR/
MCF-7, CD44
+/CD24
2 MCF-7, SKBR3 and SK-3rd. (B) The
percentage of mammospheres formed in CD44
+/CD24
2 MCF-7,
AdrR/MCF-7 and sk-3rd cell lines was significantly higher than
parental MCF-7 line and SKBR3 line (*p,0.001,mean6SD).
(TIF)
Figure S3 High proportion of side-population (SP) in
CD44
+/CD24
2 cells. (A) Representative images of SP deter-
mined by FACS analysis. (B) Compared with non-CD44
+CD24
2
MCF-7, parental MCF-7 and AdrR/MCF-7, CD44
+CD24
2
MCF-7 was more sensitive to adriamycin (*p,0.01, **p,0.001,
mean6SD). Results were from 3 independent experiments.
(TIF)
Figure S4 Expression of EGFR in breast cancer cell
lines. In comparison to the parental MCF7 cells and AdrR/
MCF7 cells, CD44
+/CD24
2 MCF-7 cells more constitutively
expressed EGFR tested by RT-PCR. This experiment was
repeated 3 times independently.
(TIF)
Figure S5 Salinomycin or lapatinib significantly reduced
mammosphere formation of sk-3rd cells by approximately 10–
100 fold relative to DMSO control (p,0.001). This experiment
was repeated 3 times independently.
(TIF)
Figure S6 Treatment with salinomycin or lapatinib reduced the
percentage of ALDH1
+ in sk-3rd cells and primary cells by 10–50
folds.
(TIF)
Figure S7 Clone forming assay from 3 independent experiments
showed that epirubicin combined with salinomycin and lapatinib
reduced the cloning efficiency of SK-3rd cells compared with
epirubicin alone (p,0.001).
(TIF)
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